Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1913

Sort by

Sort Order Select

Journal Articles

Finding the right fit: assessment of fitness in AML

Nicholas Chornenki, Lee Mozessohn

Blood Adv (2025) 9 (9): 2300–2301.

https://doi.org/10.1182/bloodadvances.2025016114

Published: 2025

Journal Articles

Is transplant success linked to donor CMV serostatus?

Steven M. Devine

Blood Adv (2025) 9 (9): 2354–2355.

https://doi.org/10.1182/bloodadvances.2025015934

Published: 2025

Journal Articles

Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT

Shunto Kawamura, Daishi Nakagawa, Takashi Nagayama, Yuta Katayama, Noriko Doki, Wataru Takeda, Tetsuya Nishida, Ken-ichi Matsuoka, Takashi Ikeda, Hiroyuki Ohigashi, Masashi Sawa, Kentaro Fukushima, Junya Kanda, Kentaro Serizawa, Makoto Onizuka, Takahiro Fukuda, Yoshiko Atsuta, Yoshinobu Kanda, Hideki Nakasone

Blood Adv (2025) 9 (9): 2356–2365.

https://doi.org/10.1182/bloodadvances.2024014408

Published: 2025

Includes: Supplemental data

Journal Articles

Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation

Rick Admiraal, Stefan Nierkens, Marc B. Bierings, Mirjam E. Belderbos, Alwin D. Huitema, Robbert G. M. Bredius, Yilin Jiang, Kevin J. Curran, Andromachi Scaradavou, Maria I. Cancio, Elizabeth Klein, Wouter J. Kollen, Dorine Bresters, Friso G. J. Calkoen, A. Birgitta Versluijs, C. Michel Zwaan, Jaap Jan Boelens, Caroline A. Lindemans

Blood Adv (2025) 9 (9): 2344–2353.

https://doi.org/10.1182/bloodadvances.2024014836

Published: 2025

Includes: Supplemental data

Journal Articles

Real-World Survival Outcomes in First-Line Ibrutinib-Treated Patients with High-Risk CLL/SLL

John N. Allan, Tao Ran, Zhijie Ding, Jinghua He, Alex Bokun, Zaina P. Qureshi, Susan M. O'Brien

Blood Adv bloodadvances.2024015417.

https://doi.org/10.1182/bloodadvances.2024015417

Published: 2025

Journal Articles

Conflating polycythemia vera with essential thrombocytosis

Jerry L. Spivak, MD, MACP

Blood Adv bloodadvances.2025016843.

https://doi.org/10.1182/bloodadvances.2025016843

Published: 2025

Journal Articles

Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results

Mazyar Shadman, John M. Burke, Jennifer Cultrera, Habte A. Yimer, Syed F. Zafar, Jamal Misleh, Subramanya S. Rao, Charles M. Farber, Aileen Cleary Cohen, Hui Yao, Adam Idoine, Qi An, Ian W. Flinn, Jeff P. Sharman

Blood Adv bloodadvances.2024015493.

https://doi.org/10.1182/bloodadvances.2024015493

Published: 2025

Includes: Supplemental data

Journal Articles

Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS

Blood Adv bloodadvances.2025016229.

https://doi.org/10.1182/bloodadvances.2025016229

Published: 2025

Includes: Supplemental data

Journal Articles

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

Blood Adv bloodadvances.2025015860.

https://doi.org/10.1182/bloodadvances.2025015860

Published: 2025

Includes: Supplemental data

Journal Articles

BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma

Katja Gutmair, Diego Villa, Nicholas Cunningham, Elisabeth Silkenstedt, Lisa Rimsza, Colleen Ramsower, David W. Scott, Alina S. Gerrie, Hanneke C. Kluin-Nelemans, Martin Dreyling, Eva Hoster

Blood Adv (2025) 9 (9): 2302–2306.

https://doi.org/10.1182/bloodadvances.2024015292

Published: 2025

Includes: Supplemental data

Journal Articles

Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: Phase 2 ESCALATE trial

Blood Adv bloodadvances.2024015102.

https://doi.org/10.1182/bloodadvances.2024015102

Published: 2025

Includes: Supplemental data

Journal Articles

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study

Elizabeth H. Phillips, Nicholas Counsell, Tim Illidge, Marc Andre, Igor Aurer, Valeria Fiaccadori, Catherine Fortpied, Anouk Neven, Massimo Federico, Sally F. Barrington, John Raemaekers, John Radford

Blood Adv (2025) 9 (9): 2266–2274.

https://doi.org/10.1182/bloodadvances.2024015140

Published: 2025

Includes: Supplemental data

Journal Articles

Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review

Luke Wang, Eliza Chung, Cameron Wellard, Allison Barraclough, Belinda A. Campbell, Geoffrey Chong, Pietro R. Di Ciaccio, Gareth P. Gregory, Greg Hapgood, Anna M. Johnston, Constantine Tam, Stephen Opat, Erica M. Wood, Zoe K. McQuilten, Eliza A. Hawkes

Blood Adv (2025) 9 (9): 2275–2284.

https://doi.org/10.1182/bloodadvances.2024015072

Published: 2025

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin and Nivolumab for Untreated Patients with Hodgkin Lymphoma: Long-term Results

Bruce David Cheson, Nancy L. Bartlett, Betsy Knopf, Hun Ju Lee, Ranjana H Advani, Beth Christian, Catherine Sibyl Diefenbach, Tatyana A. Feldman, Stephen M. Ansell

Blood Adv bloodadvances.2025016470.

https://doi.org/10.1182/bloodadvances.2025016470

Published: 2025

Journal Articles

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Blood Adv bloodadvances.2024015262.

https://doi.org/10.1182/bloodadvances.2024015262

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma

Christiane Querfeld, Joycelynne Palmer, Zhen Han, Xiwei Wu, Yate-Ching Yuan, Min-Hsuan Chen, Chingyu Su, Ni-Chun Tsai, D. Lynne Smith, Samantha N. Hammond, Liliana Crisan, Joo Y. Song, Raju Pillai, Steven T. Rosen, Jasmine Zain

Blood Adv (2025) 9 (9): 2247–2260.

https://doi.org/10.1182/bloodadvances.2024014655

Published: 2025

Includes: Supplemental data

Journal Articles

Key role of long-duration cardiac rhythm monitoring in patients with sickle cell disease with atrial hyperexcitability

Thuy Linh Dang, Thibaut Moulin, Gonzalo de Luna, Sihem Iles, Anaïs Lamadieu, David Calvet, Geneviève Derumeaux, Pablo Bartolucci, Nicolas Lellouche, Thomas d’Humières

Blood Adv (2025) 9 (9): 2261–2265.

https://doi.org/10.1182/bloodadvances.2024015307

Published: 2025

Includes: Supplemental data

Journal Articles

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma

Blood Adv (2025) 9 (9): 2232–2246.

https://doi.org/10.1182/bloodadvances.2024015577

Published: 2025

Includes: Supplemental data

Journal Articles

Reassessing the Villalta Score's Use of Signs and Symptoms

Steven Yale, Halil Tekiner, Regina Wilson, Eileen Yale

Blood Adv bloodadvances.2025016750.

https://doi.org/10.1182/bloodadvances.2025016750

Published: 2025

Journal Articles

Cutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period

Adela R. Cardones, Akintunde Emiola, Russell P. Hall, III, Anthony D. Sung, Jennifer Zhang, Amy J. Petty, Charles Puza, Lauren M. Bohannon, Amy T. Bush, Meagan V. Lew, Elizabeth Fleming, Yingai J. Jin, Krista Rowe Nichols, Vaibhav Jain, Simon G. Gregory, Keith M. Sullivan, Nelson J. Chao, Julia Oh

Blood Adv (2025) 9 (9): 2173–2182.

https://doi.org/10.1182/bloodadvances.2021004792

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Finding the right fit: assessment of fitness in AML

Is transplant success linked to donor CMV serostatus?

Impacts of donor age and HLA mismatch on HCT outcomes differ according to the donor CMV serostatus in unrelated allo-HCT

Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation

Real-World Survival Outcomes in First-Line Ibrutinib-Treated Patients with High-Risk CLL/SLL

Conflating polycythemia vera with essential thrombocytosis

Zanubrutinib is well tolerated and effective in CLL/SLL patients intolerant of ibrutinib/acalabrutinib: Updated results

Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma

Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: Phase 2 ESCALATE trial

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study

Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review

Brentuximab Vedotin and Nivolumab for Untreated Patients with Hodgkin Lymphoma: Long-term Results

Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study

Phase 1 trial of durvalumab (anti–PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma

Key role of long-duration cardiac rhythm monitoring in patients with sickle cell disease with atrial hyperexcitability

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma

Reassessing the Villalta Score's Use of Signs and Symptoms

Cutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only